DK0885210T5 - Tricykliske forbindelser med bindingsaffinitet for melatoninreceptorer, deres fremstilling og anvendelse - Google Patents

Tricykliske forbindelser med bindingsaffinitet for melatoninreceptorer, deres fremstilling og anvendelse

Info

Publication number
DK0885210T5
DK0885210T5 DK97905450T DK97905450T DK0885210T5 DK 0885210 T5 DK0885210 T5 DK 0885210T5 DK 97905450 T DK97905450 T DK 97905450T DK 97905450 T DK97905450 T DK 97905450T DK 0885210 T5 DK0885210 T5 DK 0885210T5
Authority
DK
Denmark
Prior art keywords
group
optionally substituted
substituted hydrocarbon
preparation
binding affinity
Prior art date
Application number
DK97905450T
Other languages
Danish (da)
English (en)
Other versions
DK0885210T3 (da
DK0885210T4 (da
Inventor
Shigenori Ohkawa
Osamu Uchikawa
Kohji Fukatsu
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27286462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0885210(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DK0885210T3 publication Critical patent/DK0885210T3/da
Publication of DK0885210T4 publication Critical patent/DK0885210T4/da
Application granted granted Critical
Publication of DK0885210T5 publication Critical patent/DK0885210T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
DK97905450T 1996-03-08 1997-03-05 Tricykliske forbindelser med bindingsaffinitet for melatoninreceptorer, deres fremstilling og anvendelse DK0885210T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP5149196 1996-03-08
JP18366796 1996-07-12
JP2918597 1997-02-13
PCT/JP1997/000677 WO1997032871A1 (en) 1996-03-08 1997-03-05 Tricyclic compounds, their production and use

Publications (3)

Publication Number Publication Date
DK0885210T3 DK0885210T3 (da) 2002-10-07
DK0885210T4 DK0885210T4 (da) 2008-09-08
DK0885210T5 true DK0885210T5 (da) 2008-10-13

Family

ID=27286462

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905450T DK0885210T5 (da) 1996-03-08 1997-03-05 Tricykliske forbindelser med bindingsaffinitet for melatoninreceptorer, deres fremstilling og anvendelse

Country Status (19)

Country Link
US (1) US6218429B1 (cs)
EP (2) EP1550655A1 (cs)
JP (1) JP4358917B2 (cs)
KR (1) KR100494214B1 (cs)
CN (3) CN1900067A (cs)
AT (1) ATE219071T1 (cs)
CA (1) CA2241666C (cs)
CZ (1) CZ291626B6 (cs)
DE (1) DE69713294T3 (cs)
DK (1) DK0885210T5 (cs)
ES (1) ES2175350T5 (cs)
HU (1) HU224220B1 (cs)
NO (1) NO322205B1 (cs)
NZ (1) NZ330656A (cs)
PL (1) PL188093B1 (cs)
PT (1) PT885210E (cs)
SK (1) SK283970B6 (cs)
TW (1) TW562803B (cs)
WO (1) WO1997032871A1 (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773798B1 (fr) * 1998-01-16 2001-02-02 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6348485B1 (en) 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
CA2382418A1 (en) 1999-08-20 2001-03-01 Shigenori Ohkawa Dihydrobenzofuran derivatives, process for preparing thereof and agents
DE60043017D1 (de) 1999-08-20 2009-11-05 Takeda Pharmaceutical Zusammensetzung für perkutane Absorption mit einem melantoninrezeptor-agonistisch wirkendem Wirkstoff
JP4721495B2 (ja) * 1999-08-20 2011-07-13 武田薬品工業株式会社 ジヒドロベンゾフラン誘導体、その製造法及び剤
JP4632499B2 (ja) * 1999-08-26 2011-02-16 武田薬品工業株式会社 鼻粘膜付着マトリックス
ES2262540T3 (es) * 1999-09-08 2006-12-01 Bayer Cropscience Limited Nuevas composiciones herbicidas.
ATE469644T1 (de) * 2000-11-17 2010-06-15 Takeda Pharmaceutical Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
WO2002040053A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Preparation pharmaceutique contenant du talc/ du sulfate de baryum
US6800648B2 (en) 2001-04-26 2004-10-05 Wyeth Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
TWI400220B (zh) * 2004-09-13 2013-07-01 Takeda Pharmaceutical 光活性胺衍生物的製法
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
CA2602267A1 (en) * 2005-04-04 2006-10-12 Takeda Pharmaceutical Company Limited Use of ramelteon to treat and prevent depression and anxiety disorders
EP1900368B1 (en) * 2005-06-22 2011-05-11 Takeda Pharmaceutical Company Limited Tablet containing hardly soluble active ingredient
ES2388876T3 (es) 2005-07-29 2012-10-19 Vanda Pharmaceuticals Inc. Uso de [2-(2-metilimidazol-1-il)metil]piridina para tratamiento de trastornos del sueño
BRPI0708805A2 (pt) 2006-03-20 2011-06-14 Takeda Pharmaceutical composiÇço farmacÊutica, e, uso de um composto
TWI402261B (zh) 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
AU2007329879A1 (en) 2006-12-08 2008-06-12 Takeda Pharmaceutical Company Limited Tricyclic compound and medical use thereof
JP5291470B2 (ja) * 2006-12-28 2013-09-18 武田薬品工業株式会社 三環性化合物およびその医薬用途
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
MX2009011511A (es) 2007-04-26 2009-11-12 Takeda Pharmaceutical Compuesto biciclico y uso farmaceutico del mismo.
WO2008151170A2 (en) 2007-05-31 2008-12-11 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20090105490A1 (en) * 2007-07-12 2009-04-23 Nurit Perlman Polymorphic forms of ramelteon and processes for preparation thereof
ES2324849A1 (es) * 2007-10-25 2009-08-17 Ferrer Internacional, S.A. Compuestos de indano.
US7470814B1 (en) * 2007-10-31 2008-12-30 Ferrer Internacional, S.A. Process for the preparation of substituted 7-allyl-6-hydroxy-indanes
WO2009056993A2 (en) * 2007-11-01 2009-05-07 Teva Pharmaceutical Industries Ltd. A process for the synthesis of ramelteon and its intermediates
SG185969A1 (en) * 2008-01-31 2012-12-28 Takeda Pharmaceutical Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
US8871807B2 (en) 2008-03-28 2014-10-28 Ecolab Usa Inc. Detergents capable of cleaning, bleaching, sanitizing and/or disinfecting textiles including sulfoperoxycarboxylic acids
US12203056B2 (en) 2008-03-28 2025-01-21 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
BRPI0907918B1 (pt) 2008-03-28 2018-07-24 Ecolab Inc. Ácidos sulfoperoxicarboxílicos, sua preparação e métodos de utilizção como agentes alvejantes e antimicrobianos
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
PE20110208A1 (es) * 2008-07-30 2011-03-28 Ferrer Int Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
BRPI0914068A2 (pt) * 2008-11-14 2015-10-13 Watson Pharma Private Ltd processo de resolução de n-[2-(1,6,7,8-tetra-hidro-2h-indeno[5, 4- b]furano-8-il)]etilamina e ramelteon
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
EP2396309A1 (en) 2009-02-12 2011-12-21 LEK Pharmaceuticals d.d. Synthesis of (s)-n-ý2-(1,6,7,8-tetrahydro-2h-indeno-ý5,4-b¨furan-8-yl)ethyl¨propionamide
CA2754802A1 (en) * 2009-03-10 2010-09-16 Industriale Chimica S.R.L. Process for the preparation of ramelteon
EP2243775A1 (en) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon
EP2483258A1 (en) * 2009-09-29 2012-08-08 Lonza Ltd. Process for preparing 1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-one
EP2488025A4 (en) * 2009-10-15 2013-04-03 Childrens Medical Center SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
WO2012035303A2 (en) 2010-09-17 2012-03-22 Cipla Limited Et Al A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
CN102321056B (zh) * 2011-07-29 2014-05-14 宁波人健药业集团股份有限公司 一种合成雷美替胺的方法
CN102391220A (zh) * 2011-10-10 2012-03-28 四川大学 三环乙醇类化合物及其制备方法和用途
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
MX360142B (es) 2012-03-30 2018-10-24 Ecolab Usa Inc Usos de acido peracetico/peroxido de hidrogeno y agentes reductores de peroxido para el tratamiento de fluidos de perforacion, fluidos de fracturacion y aguas de flujo de retorno y aguas de desecho.
EP2884275A4 (en) 2012-07-10 2016-04-13 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF STRESS-RELATED HARNINE CONTINENCE OR MIXED INCONTINENCE AND METHOD FOR SCREENING COMPOUNDS FOR INTRODUCTION TO THIS PHARMACEUTICAL COMPOSITION
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN103724357B (zh) * 2012-10-11 2016-06-08 中国药科大学 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
US20140256811A1 (en) 2013-03-05 2014-09-11 Ecolab Usa Inc. Efficient stabilizer in controlling self accelerated decomposition temperature of peroxycarboxylic acid compositions with mineral acids
US10165774B2 (en) 2013-03-05 2019-01-01 Ecolab Usa Inc. Defoamer useful in a peracid composition with anionic surfactants
US8822719B1 (en) 2013-03-05 2014-09-02 Ecolab Usa Inc. Peroxycarboxylic acid compositions suitable for inline optical or conductivity monitoring
AR099083A1 (es) 2014-01-14 2016-06-29 Astellas Pharma Inc Compuesto de indol
AU2017205722B2 (en) 2016-01-08 2022-02-17 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for autism spectrum disorder
EP3400940B1 (en) 2016-01-08 2024-08-07 Takeda Pharmaceutical Company Limited Compounds having melatonin receptor affinity as prophylactic or therapeutic agent for delirium
WO2021026410A1 (en) 2019-08-07 2021-02-11 Ecolab Usa Inc. Polymeric and solid-supported chelators for stabilization of peracid-containing compositions
CN110776485B (zh) * 2019-11-22 2022-09-30 山东邹平大展新材料有限公司 一种雷美替胺杂质的制备方法
WO2023059546A1 (en) * 2021-10-04 2023-04-13 Psilosterics, Llc Serotonin receptor agonists and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2713636B1 (fr) 1993-12-07 1996-01-05 Adir Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5661186A (en) 1995-02-24 1997-08-26 Bristol-Myers Squibb Co. Tetralinyl-and indanyl-ethylamides

Also Published As

Publication number Publication date
HK1087112A1 (zh) 2006-10-06
EP0885210B2 (en) 2008-06-18
DK0885210T3 (da) 2002-10-07
CN1212691A (zh) 1999-03-31
KR100494214B1 (ko) 2005-11-25
CN100441574C (zh) 2008-12-10
SK283970B6 (sk) 2004-06-08
DK0885210T4 (da) 2008-09-08
ES2175350T3 (es) 2002-11-16
JPH11152281A (ja) 1999-06-08
NZ330656A (en) 1999-06-29
HU224220B1 (hu) 2005-06-28
ES2175350T5 (es) 2008-12-16
PL188093B1 (pl) 2004-12-31
SK115098A3 (en) 1999-03-12
NO322205B1 (no) 2006-08-28
KR19990087628A (ko) 1999-12-27
US6218429B1 (en) 2001-04-17
DE69713294T2 (de) 2003-02-13
NO983970L (no) 1998-08-28
CN1900067A (zh) 2007-01-24
DE69713294D1 (de) 2002-07-18
AU706610B2 (en) 1999-06-17
TW562803B (en) 2003-11-21
HUP9900616A3 (en) 2002-11-28
HUP9900616A2 (hu) 1999-06-28
EP0885210A1 (en) 1998-12-23
EP0885210B1 (en) 2002-06-12
CZ277598A3 (cs) 1998-12-16
CN1727339A (zh) 2006-02-01
JP4358917B2 (ja) 2009-11-04
CN100443480C (zh) 2008-12-17
DE69713294T3 (de) 2009-01-15
NO983970D0 (no) 1998-08-28
PT885210E (pt) 2002-09-30
CA2241666C (en) 2007-11-06
EP1550655A1 (en) 2005-07-06
CZ291626B6 (cs) 2003-04-16
PL328726A1 (en) 1999-02-15
WO1997032871A1 (en) 1997-09-12
AU2231897A (en) 1997-09-22
ATE219071T1 (de) 2002-06-15
CA2241666A1 (en) 1997-09-12

Similar Documents

Publication Publication Date Title
DK0885210T3 (da) Tricykliske forbindelser med bindingsaffinitet for melatoninreceptorer, deres fremstilling og anvendelse
NO800034L (no) Nye (piperidinylalkyl)kinazolinderivater samt fremgangsmaate til deres fremstilling
KR950704313A (ko) 5-아릴인돌 유도체 및 세로토닌(5-ht₁)작용물질로서의 그의 용도(5-arylindole derivatives and their use as serotonin(5-ht₁)agonists)
ES2126075T3 (es) Derivados biciclicos nitrogenados como inhibidores de la propil-endopeptidasa.
ES2039221T3 (es) Procedimiento para producir derivados de piridazinona.
DK640889A (da) Fenylderivater med antidiabetisk, isaer hypoglykaemisk virkning
BR0013075A (pt) Derivados de tetrazolinona
DE69904604D1 (de) Starkes grünstichiges gelbes disazopigment
DK415789A (da) Tetracykliske antidepressive midler
ATE137747T1 (de) Aminobenzolverbindungen, herstellung und verwendung
EA200400770A1 (ru) Производные 5-(пиридин-3-ил)-1-азабицикло[3.2.1]октана, их получение и применение в терапии
ATE269329T1 (de) Neue basische derivate von benz(e)isoindol-1-onen und pyrrolo(3,4-c)chinolin-1-onen mit 5-ht3- antagonistischer aktivität, ihre herstellung und ihre therapeutische verwendung
DE3061188D1 (en) 2-sulfonyl-quinoxalines, processes for their preparation and their use as microbicides
ATE96424T1 (de) Mit einer cyanogruppe substituierte nitroanilin- farbstoffe.
WO2001064671A3 (fr) Derives d'haloimidazole et leur utilisation en tant qu'antagonistes des recepteurs muscariniques m3 et serotoniques 5-ht4
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.